|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of goods sold | |||||
| Gross profit | |||||
| Selling, general, and administrative expense | |||||
| Research and development expense | |||||
| Restructuring, asset-related, and other charges | |||||
| Goodwill impairment charge | |||||
| Total other operating expenses | |||||
| Equity in earnings of affiliates | |||||
| Interest expense, net | |||||
| Loss on extinguishment of debt | |||||
| Other income, net | |||||
| (Loss) Income before income taxes | |||||
| (Benefit from) provision for income taxes | |||||
| Net (loss) income | |||||
| Less: Net income attributable to non-controlling interests | |||||
| Net (loss) income attributable to Chemours | |||||
| Per share data | |||||
| Basic (loss) earnings per share of common stock | |||||
| Diluted (loss) earnings per share of common stock |
Loading...
